UNSPSC 51111802: Bicalutamide

This classification denotes an anti-androgen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A0Z3NAU9DP. European Medicines Agency schedules Bicalutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05817MIG. Bicalutamide generally arises in the molecular formula C18H14F4N2O4S.

UNSPSC 51111802 Bicalutamide is a Commodity code covering the procurement of this specific antineoplastic pharmaceutical product by state and local health authorities. Based on recent solicitation activity, state and local governments acquire bicalutamide through cooperative purchasing arrangements that consolidate demand across multiple jurisdictions and facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issues broad RFPs for generic multi-source pharmaceuticals and OTC products that include bicalutamide alongside other therapeutic categories, with awarded manufacturers required to meet current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with authorized wholesalers, and provide detailed product data including National Drug Codes, SKUs, and UPCs. Issuing bodies under this code include state health departments and cooperative purchasing consortia that aggregate demand across participating state agencies, counties, and local health systems; MMCAP serves participating jurisdictions in Minnesota, Oregon, and other member states.

Geographic activity centers on the upper Midwest and Pacific Northwest through MMCAP's multi-state vehicle. The most recent solicitation is MMCAP's RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products, posted January 20, 2026, with proposals due March 26, 2026 and questions closed as of February 18, 2026. Evaluation emphasizes price competitiveness (75 percent of scoring) alongside pricing format flexibility, administrative compliance, EDI capability, and a mandatory 3 percent administrative fee on all purchases. Awarded vendors supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with resulting contracts effective July 1, 2026 for an initial two-year term. Insurance requirements include $5 million commercial general liability per occurrence and $2 million network security and privacy liability; all products must carry expiration dates at least one year from manufacture with a minimum six-month shelf life remaining at delivery.